

PROF. PETER J COWAN (Orcid ID : 0000-0001-9016-4954)

Article type : M - Minireview

## **The Resurgence of Xenotransplantation**

Peter J. Cowan, PhD<sup>1,2</sup> and A. Joseph Tector, MD, PhD<sup>3</sup>

<sup>1</sup> Immunology Research Centre, St Vincent's Hospital Melbourne, Victoria, Australia.

<sup>2</sup> Department of Medicine, University of Melbourne, Victoria, Australia.

<sup>3</sup> School of Medicine, University of Alabama, Birmingham, AL.

**Corresponding author email:** peter.cowan@svha.org.au

**Running title:** The Resurgence of Xenotransplantation

### **Abbreviations:**

CVF: cobra venom factor

Gal: galactose- $\alpha$ -1,3-galactose

GTKO:  $\alpha$ 1,3-galactosyltransferase gene knock-out

HAR: hyperacute rejection

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/ajt.14311](https://doi.org/10.1111/ajt.14311)

This article is protected by copyright. All rights reserved

IBMIR: instant blood-mediated inflammatory reaction

IEQ: islet equivalents

MST: median survival time

NHP: nonhuman primate

PERV: porcine endogenous retrovirus

WT: wild type

## **Abstract**

There has been an upsurge of interest in xenotransplantation in recent years. This resurgence can be attributed to a combination of factors. First, there has been a dramatic improvement in efficacy in several preclinical models, with maximum xenograft survival times increasing to 950 days for islets, 945 days for hearts, and 310 days for kidneys. Second, the rapid development of genome editing technology (particularly the advent of CRISPR/Cas9) has revolutionized the capacity to generate new donor pigs with multiple protective genetic modifications; what once took many years to achieve can now be performed in months, with much greater precision and scope. Third, the spectre of porcine endogenous retrovirus (PERV) has receded significantly. There has been no evidence of PERV transmission in clinical trials and preclinical models, and improved screening methods and new options for the treatment or even elimination of PERV are now available. Balancing these positive developments are several remaining challenges, notably the heavy and often clinically inapplicable immunosuppression required to prevent xenograft rejection. Nonetheless, the potential for xenotransplantation as a solution to the shortage of human organs and tissues for transplantation continues to grow.

## **Introduction**

Xenotransplantation has always offered great promise to address the widening gap between

demand and supply in transplantation. However, enthusiasm for xenotransplantation waned in the early 2000s due to slow progress in pig-to-nonhuman primate (NHP) preclinical models and fears about zoonosis, particularly in relation to PERV. This review will examine the recent resurgence of activity and interest in xenotransplantation, and the underlying factors involved. We will begin by discussing the promise and potential impact of genome editing, which will enable genetic manipulation of the donor pig on a previously unimaginable scale. We will then discuss progress in clinical trials and NHP studies of solid organ and tissue xenotransplantation within the last 5 years. We will conclude by re-visiting the question of infectious risk, in the light of recent developments.

### **Genome Editing**

Genetic modification is a key technique aimed at creating pigs whose organs and tissues have decreased antigenicity and increased physiological compatibility with humans. Until recently, this goal had been hampered by technological limitations. The generation of a homozygous single gene knockout pig using traditional homologous recombination might take three years from start to finish. This process has been revolutionized by the development of genome editing: first, zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), and more recently the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system. CRISPR/Cas9 is increasingly favoured due to its ease of use and versatility, including its capacity to simultaneously modify multiple genes in a single reaction (1). The power of CRISPR/Cas9 is illustrated by its use to produce pigs with homozygous triple knockouts, either of SLA class I genes (2) or of genes encoding carbohydrate xenoantigens (3), in a process taking months rather than years. Furthermore, CRISPR/Cas9 can bypass the requirement for the inefficient and technically challenging technique of somatic cell nuclear transfer to generate knockout pigs; the CRISPR/Cas9 components can simply be injected into porcine zygotes, which are subsequently transferred into foster mothers (4). CRISPR/Cas9 also offers the opportunity to precisely knock transgenes into the pig genome (5).

The potential of genome editing can be glimpsed in a study examining the effect of CRISPR-mediated deletion of multiple xenoantigens on the histocompatibility of pig cells with human serum (3). CRISPR/Cas9 was used to generate *GGTA1/CMAH/B4GALNT2* triple knockout

pigs, which lack expression of the non-human carbohydrates galactose- $\alpha$ 1,3-galactose and *N*-glycolylneuraminic acid as well as an SD<sup>a</sup> antigen-like glycan. Crossmatching human serum with porcine peripheral blood mononuclear cells revealed that a significant proportion of renal transplant waitlisted patients had a negative IgG crossmatch to these pigs, and a sizeable percentage had a negative IgM and IgG crossmatch. These promising results suggest that the threat posed by pre-existing antibodies in some patients may be reduced by genome editing of the donor pig. The news for highly sensitized (cPRA >80) patients was not as good, as many of those patients had a positive crossmatch to the triple knockout pigs, probably due to cross reaction of anti-HLA antibodies with SLA class I molecules (3). However, with the precision afforded by CRISPR/Cas9, rational modification of SLA class I genes may eventually provide a solution to even this problem.

### **Islet Xenotransplantation**

Of all types of xenotransplantation, transplanting porcine islets to treat type 1 diabetes is generally viewed as the most likely to reach the clinic first. The form that this takes – intraportal delivery of ‘naked’ islets as practiced in clinical allotransplantation, or an alternative transplant site and/or some means of encapsulation – will ultimately depend on which method provides the optimal balance of efficacy, safety and cost. Clinical trials of microencapsulated wild type (WT) neonatal porcine islets transplanted in the absence of immunosuppression have been performed in New Zealand and Argentina (6, 7). Alginate microcapsules containing 5,000 to 20,000 islet equivalents (IEQ) per kg body weight were transplanted intraperitoneally either as a single dose in 14 diabetic patients (6), or as two equal doses 3 months apart in 8 diabetic patients (7). Although there was no significant reduction in insulin dose in any group, patients receiving two transplants of 10,000 IEQ/kg showed a significant long-term (>600 days) decrease in HbA1c and a reduction in serious unaware hypoglycemic events (7). The procedure was safe, with minimal adverse events and no evidence of zoonosis (6, 8), but improved efficacy is clearly required to warrant clinical application.

Intraportal islet xenotransplantation, on the other hand, has demonstrated convincing efficacy in preclinical nonhuman primate (NHP) models. A key recent study showed that WT adult pig islet xenografts maintained insulin-independent normoglycemia for a median of 303 days (maximum

950 days, Fig. 1) in five consecutive diabetic monkey recipients (9, 10). However, a drawback of the procedure was the relatively high dose of islets required (80,000-100,000 IEQ/kg). The study also highlighted that control of the inflammatory/immune response is a greater issue for porcine islets than it is for allogeneic islets. Recipients were treated with a complex protocol, including a cocktail of agents to minimize the instant blood-mediated inflammatory reaction (IBMIR), and long-term immunosuppression to inhibit cellular and humoral immune responses (9), which is not feasible for most prospective islet graft recipients. Several strategies to tackle the problems of IBMIR and chronic immunosuppression are being pursued. Studies in baboons (11) and monkeys (12) suggest that IBMIR can be reduced by using genetically modified (GTKO  $\pm$  hCD55-hCD59) neonatal pig islets. Shin *et al* (9, 10) attempted to induce tolerance to porcine islet xenografts in a pig-to-monkey model by adoptively transferring *ex vivo* expanded regulatory T cells, but grafts were rejected when maintenance immunosuppression was discontinued. Another option is genetic modification to engineer local production of immunosuppressive agents by the xenograft itself (13-15), although the efficacy of this strategy has not been directly tested in NHP preclinical models.

### **Heart Xenotransplantation**

The heterotopic pig-to-NHP cardiac xenotransplantation model has been another area in which there have been major recent advances. Mohiuddin *et al* achieved a median survival time (MST) of 298 days (maximum 945 days) in five consecutive baboons transplanted with hearts from *GGTA1* knockout (GTKO) pigs transgenic for human CD46 and thrombomodulin (16). The immunosuppressive regimen was induction with anti-thymocyte globulin (ATG), anti-CD20, and cobra venom factor (CVF), and maintenance with anti-CD40, mycophenolate mofetil, steroids, and continuous heparin. Intensive and ongoing treatment with anti-CD40 was required for long-term graft survival. It was suggested that the expression of human thrombomodulin may be important to prevent the development of dysregulated coagulation, although this was not formally demonstrated. At a practical level, there was no indication that a pig cardiac xenograft would retain its natural rate of development and thus 'outgrow' the abdominal space of the recipient (16). This remains an open question, as Abicht *et al* reported a significant enlargement of porcine intrathoracic cardiac xenografts in baboon recipients, although it was not possible to distinguish between physiological growth and pathological changes due to humoral rejection (17).

Furthermore, Tanabe *et al* recently reported hypertrophy of porcine kidney xenografts in baboons, and cautioned that the growth of donor organs – due at least in part to intrinsic factors – should be taken into account when transplanting life-supporting xenografts into a limited space (18).

A major challenge for the cardiac field is to translate these exciting results to an orthotopic life-supporting setting. Maximum survival in the extremely challenging pig-to-NHP orthotopic model is just 57 days (19). Results to date suggest that a phenomenon termed perioperative cardiac xenograft dysfunction (PCXD), and not rejection, is the current barrier to long-term survival (20). PCXD occurs in 40-60% of cases and can be reversible in the first two perioperative weeks. Histological analysis of cardiac xenografts that failed secondary to PCXD showed no signs of rejection, rather a picture more similar to cardiac stunning or ischemia/reperfusion injury. Until the underlying mechanism is delineated, it will be difficult to design therapies or genetic engineering strategies to prevent PCXD.

### **Kidney Xenotransplantation**

The generation of CRISPR-modified pigs with improved histocompatibility with renal transplant waitlisted patients (3) has coincided with significant progress in other areas of kidney xenotransplantation. Two groups have achieved greater than 7-month survival (maximum 310 days) in pig-to-NHP preclinical models (21-23), demonstrating that prolonged life-supporting function is achievable. Of note, the recipients in these studies did not exhibit proteinuria, which had been identified in earlier studies as a major obstacle in kidney xenotransplantation. It remains unclear whether proteinuria in the context of renal xenografts is secondary to antibody-mediated rejection (as is the case for renal allografts) or is due to a physiological incompatibility and unrelated to rejection (24).

Both groups stressed the potential importance of (i) the donor pig genotype common to the studies (GTKO plus one or two human complement regulatory proteins), and (ii) effective costimulation blockade. In addition, Higginbotham *et al* (21) found that long-term graft survival was associated with low levels of pre-existing donor-specific antibodies, whereas Iwase *et al* (22) proposed the potential importance of anti-inflammatory therapy and the expression of an additional human transgene for the anti-coagulant, anti-inflammatory endothelial protein C receptor (EPCR). There

were several differences between the models, including the recipient species (baboon (22) or rhesus monkey (21)) and the immunosuppressive regimen (ATG/ anti-CD20/ anti-CD40/ rapamycin (22) or anti-CD4/ anti-CD8/ anti-CD154/ MMF (21)). This makes it difficult to identify the factor(s) responsible for the major prolongation of maximum survival from the previous record of 3 months (23). Nevertheless, if routine prolonged survival using clinically available immunosuppression can be demonstrated in the NHP model, then progression to a clinical trial with recipients with a negative crossmatch may be justified.

The NHP kidney xenograft model has been a critical test bed for the study of xenogeneic tolerance by Yamada, Sachs and colleagues, who have investigated ‘thymokidney’ and mixed chimerism strategies. Most recently, refinements in the latter have prolonged the duration of macro-chimerism and the survival of life-supporting GTKO kidney xenografts (25).

### **Liver Xenotransplantation**

Until recently, survival in pig-to-NHP liver xenotransplantation was limited to 9 days by a lethal thrombocytopenic coagulopathy that developed in the early post-transplant period (26). Different approaches have been taken to tackle this problem. One strategy is to identify the cause of coagulopathy and attempt to correct it by genetic modification of the donor pig. Pig liver sinusoidal endothelial cells (LSEC) were found to phagocytose human and NHP platelets by a mechanism involving the asialoglycoprotein receptor (ASGR) (27). ASGR1 knockout pigs were generated and their livers were shown to phagocytose significantly fewer human platelets than WT livers in an *ex vivo* perfusion circuit (28). Unexpectedly, livers from *GGTA1/CMAH* double knockout pigs also sequestered fewer human platelets than WT or *GGTA1* knockout (GTKO) livers *ex vivo* (29). However, the *in vivo* impact of these genetic modifications has not yet been tested, and indeed the *GGTA1/CMAH* double knockout pigs cannot be fully tested in the NHP model because Old World primates, unlike humans, have a functional *CMAH* gene.

Another approach to preventing liver xenograft-induced coagulopathy has been to treat the recipient with recombinant human coagulation factors, based on the observation of marginal coagulation factor production in baboon recipients. In the first of two studies using GTKO pig donors, baboons were immunosuppressed with ATG, CVF, tacrolimus and steroids, and treated

with Octaplex (human coagulation factors II, VII, IX, X, protein C and protein S) or NovoSeven (factor VIIa) (30). The coagulation factor treatment rendered post-transplant thrombocytopenia manageable and eliminated the need for platelet transfusions. However, survival of the 6 recipients was limited to a maximum of 7 days, mainly due to thrombosis or intra-abdominal bacterial infection. This highlighted the fine line between bleeding and clotting that hemostasis requires, as well as the infectious risks of surgical re-exploration in the early post-operative period. In the second study, the same group transplanted a single baboon with the Octaplex protocol, adding belatacept to the maintenance therapy and avoiding re-exploration (31). This recipient developed a transient thrombocytopenia that spontaneously recovered within 2 weeks, and survived for 25 days without evidence of rejection or thrombosis. Although these results are preliminary, they suggest that a pig liver may be capable of maintaining life long enough to be used as a bridge to transplant, with the potential for further advances using donors that have been genetically modified to avoid thrombocytopenia (28, 29).

### **Lung Xenotransplantation**

Lungs present perhaps the greatest challenge in solid organ xenotransplantation. Despite the testing of numerous genetic modifications and treatments to inhibit the innate and adaptive immune responses, complement, coagulation, and inflammation, maximum survival of life-supporting lung xenografts in the NHP model remains limited to 8 days (32).

### **Corneal and Tissue Xenotransplantation**

Corneal xenotransplantation faces unique anatomical and surgical challenges, although recent progress in NHP models suggest that these are not insurmountable (reviewed in (33)). The survival of WT pig full thickness corneal xenografts in monkeys treated with anti-CD154-based immunosuppression (MST 318 days; maximum >933 days) was significantly greater than in monkeys treated with steroids alone (MST 28 days; maximum 29 days) (34). *In vitro* studies suggest that the immunogenicity of pig corneas can be reduced by genetic modification (35), but whether this will permit a reduction in immunosuppression remains to be determined.

Intracerebral transplantation of porcine neural tissue or choroid plexus, which secretes



neurotrophic and neuroprotective factors, has been proposed as a treatment for Parkinson's Disease. In a study in which Parkinsonian monkeys were transplanted with porcine embryonic neuroblasts, maturation of the xenografts and a significant improvement in clinical symptoms were observed at 6 months post-transplant in immunosuppressed recipients (36). Improved neurological scores were also observed at 6 months in Parkinsonian monkeys transplanted with microencapsulated porcine neonatal choroid plexus cells, in the absence of immunosuppression (37). The microcapsules are currently being tested in a Phase IIb clinical trial in New Zealand.

### **Infectious Risk**

The risk posed by the xenograft as a potential carrier of bacterial, fungal or viral pathogens can be minimized by careful screening of donor pigs and their maintenance in specific or designated pathogen-free facilities (reviewed recently in (38)). The definition of 'pathogen-free' is somewhat fluid, and the screening strategy may differ depending on multiple factors such as the location and relative isolation of the facility (6, 39, 40). Microbiological safety data have been gathered from preclinical and clinical trials using encapsulated islets from 'high health status' pigs. Six non-immunosuppressed monkey recipients showed no evidence of transmission of viruses of possible concern (PCV, PLHV, PRRSV, PCMV and PERV) at 1 year and up to 4 years post-transplant (39). Similarly, no transmission of PCV, PLHV, PCMV or PERV was detected in 14 non-immunosuppressed human recipients up to 1 year post-transplant (6). Although the potential risk is increased with the use of immunosuppression, which will likely be required for most forms of xenotransplantation, these initial results are nevertheless encouraging.

From a theoretical standpoint, PERV (porcine endogenous retrovirus) represents the most serious challenge because it is present at multiple copies in the pig genome, and thus unlike other viral pathogens cannot be eliminated by breeding. Although there has been no evidence to date of PERV transmission from pigs to humans or NHPs (38), the International Xenotransplantation Association advocates a cautious approach, including screening of donor pigs for low PERV expression levels and monitoring of xenograft recipients (41). The absence of PERV transmission in the 14 patients mentioned above, and in 8 subsequent recipients of encapsulated porcine islets confirmed PERV-negative by PCR and serology at 1 year post-transplant (8), supports this approach. In the unlikely event of PERV infection of recipients, recent *in vitro* studies suggest that

several licensed retroviral inhibitors used to treat HIV will also be efficacious against PERV (42, 43). Furthermore, it may be possible to completely eliminate the risk of PERV by gene editing of the donor pig. Yang et al. (44) used CRISPR/Cas9 to knock out all 62 copies of PERV in a pig cell line, reducing PERV transmission to human cells *in vitro* >1000-fold. However, it remains to be determined whether a healthy pig with a PERV-free genome can be generated.

## Summary

Clinical xenotransplantation remains a daunting challenge, particularly for sensitive organs such as the lung, but the pace of progress in several areas suggests that clinical trials may no longer be a distant prospect.

## Disclosure

The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. PJC is a member of the Scientific Advisory Board of Hunan Xeno Life Sciences Inc. AJT is the founder of Xenobridge LLC and has patents pending.

## Figure Legends

**Figure 1.** Survival and function of a WT pig islet xenograft for 950 days in an immunosuppressed rhesus monkey. Reproduced with permission from (10).

## References


1. Cowan PJ. The use of CRISPR/Cas associated technologies for cell transplant applications. *Curr Opin Organ Transplant*. 2016; 21: 461-6.
2. Reyes LM, Estrada JL, Wang ZY, et al. Creating class I MHC-null pigs using guide RNA and the Cas9 endonuclease. *J Immunol* 2014; 193: 5751-7.

3. Martens GR, Reyes LM, Butler JR, et al. Humoral Reactivity of Renal Transplant-Waitlisted Patients to Cells from GGTA1/CMAH/B4GalNT2, and SLA Class I Knockout Pigs. *Transplantation* 2017; Jan 21 (Epub before print).
4. Petersen B, Frenzel A, Lucas-Hahn A, et al. Efficient production of biallelic GGTA1 knockout pigs by cytoplasmic microinjection of CRISPR/Cas9 into zygotes. *Xenotransplantation* 2016; 23: 338-46.
5. Peng J, Wang Y, Jiang J, et al. Production of Human Albumin in Pigs Through CRISPR/Cas9-Mediated Knockin of Human cDNA into Swine Albumin Locus in the Zygotes. *Scientific Reports* 2015; 5: 16705.
6. Wynyard S, Nathu D, Garkavenko O, Denner J, Elliott R. Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand. *Xenotransplantation* 2014; 21: 309-23.
7. Matsumoto S, Abalovich A, Wechsler C, Wynyard S, Elliott RB. Clinical Benefit of Islet Xenotransplantation for the Treatment of Type 1 Diabetes. *EBioMedicine* 2016; 12: 255-62.
8. Morozov VA, Wynyard S, Matsumoto S, et al. No PERV transmission during a clinical trial of pig islet cell transplantation. *Virus Research* 2017; 227: 34-40.
9. Shin JS, Kim JM, Kim JS, et al. Long-term control of diabetes in immunosuppressed nonhuman primates (NHP) by the transplantation of adult porcine islets. *Am J Transplant* 2015; 15: 2837-50.
10. Shin JS, Min BH, Kim JM, et al. Failure of transplantation tolerance induction by autologous regulatory T cells in the pig-to-non-human primate islet xenotransplantation model. *Xenotransplantation* 2016; 23: 300-9.
11. Hawthorne WJ, Salvaris EJ, Phillips P, et al. Control of IBMIR in neonatal porcine islet xenotransplantation in baboons. *Am J Transplant* 2014; 14: 1300-9.
12. Thompson P, Badell IR, Lowe M, et al. Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function. *Am J Transplant* 2011; 11: 2593-602.
13. Brady JL, Sutherland RM, Hancock M, et al. Anti-CD2 producing pig xenografts effect localized depletion of human T cells in a huSCID model. *Xenotransplantation* 2013; 20: 100-9.
14. Klymiuk N, van Buerck L, Bahr A, et al. Xenografted islet cell clusters from INSLEA29Y transgenic pigs rescue diabetes and prevent immune rejection in humanized mice. *Diabetes* 2012; 61: 1527-32.

15. Bottino R, Wijkstrom M, van der Windt DJ, et al. Pig-to-monkey islet xenotransplantation using multi-transgenic pigs. *Am J Transplant* 2014; 14:2275-87.
16. Mohiuddin MM, Singh AK, Corcoran PC, et al. Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft. *Nature Communications* 2016; 7:11138.
17. Abicht JM, Mayr T, Reichart B, et al. Pre-clinical heterotopic intrathoracic heart xenotransplantation: a possibly useful clinical technique. *Xenotransplantation* 2015; 22:427-42.
18. Tanabe T, Watanabe H, Shah JA, et al. Role of Intrinsic (Graft) Versus Extrinsic (Host) Factors in the Growth of Transplanted Organs Following Allogeneic and Xenogeneic Transplantation. *Am J Transplant* 2017; Jan 24 (Epub before print).
19. Mohiuddin MM, Reichart B, Byrne GW, McGregor CG. Current status of pig heart xenotransplantation. *Int J Surg* 2015; 23(Pt B): 234-9.
20. Byrne GW, Azimzadeh AM, Ezzelarab M, et al. Histopathologic insights into the mechanism of anti-non-Gal antibody-mediated pig cardiac xenograft rejection. *Xenotransplantation* 2013; 20: 292-307.
21. Higginbotham L, Mathews D, Breeden CA, et al. Pre-transplant antibody screening and anti-CD154 costimulation blockade promote long-term xenograft survival in a pig-to-primate kidney transplant model. *Xenotransplantation* 2015; 22: 221-30.
22. Iwase H, Liu H, Wijkstrom M, et al. Pig kidney graft survival in a baboon for 136 days: longest life-supporting organ graft survival to date. *Xenotransplantation* 2015; 22: 302-9.
23. Wijkstrom M, Iwase H, Paris W, et al. Renal xenotransplantation: experimental progress and clinical prospects. *Kidney Int* 2017; 91: 790-6.
24. Tasaki M, Shimizu A, Hanekamp I, et al. Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation. *J Am Soc Nephrol* 2014; 25: 737-44.
25. Tasaki M, Wamala I, Tena A, et al. High incidence of xenogenic bone marrow engraftment in pig-to-baboon intra-bone bone marrow transplantation. *Am J Transplant* 2015; 15: 974-83.
26. Kim K, Schuetz C, Elias N, et al. Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons. *Xenotransplantation* 2012; 19: 256-64.

27. Paris LL, Chihara RK, Reyes LM, et al. ASGR1 expressed by porcine enriched liver sinusoidal endothelial cells mediates human platelet phagocytosis in vitro. *Xenotransplantation* 2011; 18: 245-51.
28. Paris LL, Estrada JL, Li P, et al. Reduced human platelet uptake by pig livers deficient in the asialoglycoprotein receptor 1 protein. *Xenotransplantation* 2015; 22: 203-10.
29. Butler JR, Paris LL, Blankenship RL, et al. Silencing Porcine CMAH and GGTA1 Genes Significantly Reduces Xenogeneic Consumption of Human Platelets by Porcine Livers. *Transplantation* 2016; 100: 571-6.
30. Navarro-Alvarez N, Shah JA, Zhu A, et al. The Effects of Exogenous Administration of Human Coagulation Factors Following Pig-to-Baboon Liver Xenotransplantation. *Am J Transplant* 2016; 16: 1715-25.
31. Shah JA, Navarro-Alvarez N, DeFazio M, et al. A Bridge to Somewhere: 25-day Survival After Pig-to-Baboon Liver Xenotransplantation. *Annals of Surgery* 2016; 263: 1069-71.
32. Kubicki N, Laird C, Burdorf L, Pierson RN, 3rd, Azimzadeh AM. Current status of pig lung xenotransplantation. *Int J Surg* 2015; 23(Pt B): 247-54.
33. Kim MK, Hara H. Current status of corneal xenotransplantation. *Int J Surg* 2015; 23(Pt B): 255-60.
34. Choi HJ, Lee JJ, Kim DH, et al. Blockade of CD40-CD154 costimulatory pathway promotes long-term survival of full-thickness porcine corneal grafts in nonhuman primates: clinically applicable xenocorneal transplantation. *Am J Transplant* 2015; 15:628-41.
35. Lee W, Hara H, Ezzelarab MB, et al. Initial in vitro studies on tissues and cells from GTKO/CD46/NeuGcKO pigs. *Xenotransplantation* 2016; 23: 137-50.
36. Aron Badin R, Vadori M, Vanhove B, et al. Cell therapy for Parkinson's disease: A translational approach to assess the role of local and systemic immunosuppression. *Am J Transplant* 2016; 16: 2016-29.
37. Luo XM, Lin H, Wang W, et al. Recovery of neurological functions in non-human primate model of Parkinson's disease by transplantation of encapsulated neonatal porcine choroid plexus cells. *Journal of Parkinson's disease* 2013; 3: 275-91.
38. Denner J, Mueller NJ. Preventing transfer of infectious agents. *Int J Surg* 2015; 23(Pt B): 306-11.

39. Gazda LS, Collins J, Lovatt A, et al. A comprehensive microbiological safety approach for agarose encapsulated porcine islets intended for clinical trials. *Xenotransplantation* 2016; 23: 444-63.
40. Schuurman HJ. Microbiological safety of clinical xenotransplantation products: monitoring strategies and regulatory aspects. A commentary. *Xenotransplantation* 2016; 23: 440-3.
41. Spizzo T, Denner J, Gazda L, et al. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 2a: source pigs--preventing xenozoonoses. *Xenotransplantation* 2016; 23: 25-31.
42. Demange A, Yajjou-Hamalian H, Gallay K, et al. Porcine endogenous retrovirus-A/C: biochemical properties of its integrase and susceptibility to raltegravir. *J Gen Virol* 2015; 96: 3124-30.
43. Argaw T, Colon-Moran W, Wilson C. Susceptibility of porcine endogenous retrovirus to anti-retroviral inhibitors. *Xenotransplantation* 2016; 23: 151-8.
44. Yang L, Guell M, Niu D, et al. Genome-wide inactivation of porcine endogenous retroviruses (PERVs). *Science* 2015; 350: 1101-4.



**Figure 1.** Survival and function of a WT pig islet xenograft for 950 days in an immunosuppressed rhesus monkey. Reproduced with permission from (10).